We reported previously that PBMC from HIV+ patients spontaneously release increased levels of TGF beta 1, contributing to defects in cellular immune responses. This study defines the implications of TGF beta overexpression for humoral immunity in HIV infection. We found that upon Staphylococcus aureus Cowan I (SAC) stimulation of cells from HIV+ donors, B-lymphocyte proliferative responses were decreased. This deficiency correlated closely (r = 0.7, P less than 0.001) with increased TGF beta secretion by PBMC from HIVinfected donors. Conditioned medium from HIV+ PBMC and purified TGF beta 1 had similar inhibitory effects on SAC-or EBV-induced B-cell proliferation, and B cells from HIV-infected donors were as sensitive to inhibition by TGF beta as cells from normal donors. Antibodies to TGF beta 1 neutralized the inhibitory effect of HIV+ culture supernatants on normal B cells and increased low proliferative responses by HIV+ cells. Using PWM as stimulus for B cell differentiation, it was shown that activated TGF beta from HIV+ PBMC is able to significantly reduce the induction of immunoglobulins and this effect was also abrogated by anti-TGF beta. These studies support the concept that in HIV infection, TGF beta is a potent suppressor, not only of the cellular, but of the humoral immune responses as well.
Introduction
Infection with HIV results in severe quantitative and qualitative defects of cellular and humoral immune responses (1) (2) (3) . Humoral immune abnormalities include polyclonal B cell activation with hypergammaglobulinemia, circulating immune complexes, and autoantibodies. B cell function in AIDS is characterized by reduced or absent responses to both T cell-dependent and -independent B cell activators and by an elevation in spontaneous immunoglobulin secretion (4) (5) (6) (7) . In spite of these signs of spontaneous B cell hyperactivity, antibody responses to both recall antigens and new antigens are frequently deficient (6, 8) .
Such B cell dysfunction in HIV+ individuals may increase susceptibility to secondary infections. This impairment of B cell function also has consequences for the diagnosis and management ofHIV infection and its sequelae, and may be a significant host factor that could interfere with successful immunization against HIV.
Our recent studies have documented that TGF,B is overexpressed in HIV infection (9) . It exerts very potent inhibitory effects on diverse aspects of cellular immunity. In addition, we have shown that TGFf induces T cell dysfunction that is not related to cytopathic depletion of CD4+ helper cells in HIV infection. Through such effects on T cells, but also through direct effects on B-lymphocytes, TGF,B has the potential to contribute to the, as yet, unexplained humoral immune defects in HIV infection.
This study investigates the consequences of TGF,3 overexpression in HIV infection with respect to growth and differentiation of B cells. The data support the concept that this cytokine may also be an important factor in the development of humoral immunodeficiency.
Methods
Patient characteristics. The group of HIV+ donors (n = 32) included 10 patients with AIDS (Centers of Disease Control, group IV), 9 patients with CDC II, and 13 patients with CDC III (10). All patients belonged to the risk group of homosexuals and had no history of intravenous drug abuse. Data on current medical treatment are shown in Table I . The control group consisted of 32 age-matched healthy heterosexual men. Measurements of lymphocyte subsets were performed by standard flow cytometry (EPICS coulter counter; Coulter Corp., Hialeah, FL) .
Isolation andfractionation ofPBMC. Heparinized blood from patients or controls was fractionated using a standard Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO) density gradient to isolate PBMC. Purified B-or T-lymphocytes (> 95% pure) were obtained by E-rosetting and monocyte depletion using adherence to polystyrene culture dishes that had been preincubated with autologous plasma ( 11 TGFff determination. Supernatants were collected from 24-h PBMC cultures. Samples were tested for TGF# activity with and without transient acidification (reduction of the pH in the supernatants to pH 1.5 by the addition of5 N HCI and neutralization with 1.4 N NaOH in 0.7 M Hepes) (12) . Titers ofTGF,B are expressed in ng/ml based on a standard curve generated by using purified porcine TGF, (R&D Systems, Minneapolis, MN). This was performed with each set of assays.
The isoform of TGF,3 secreted by PBMC was determined by antibody neutralization. Specificity of the antibodies used to neutralize active TGF,B was demonstrated by comparing their effects in the CCL64 and in the lymphocyte activating factor (LAF) assays (13) . TGF,BI and TGFI32 were neutralized to the same extent by the antibody recognizing both TGF#I and fl2 (12.5 gg/ml of antibody completely neutralized 1 ng/ml TGF# I or TGF,B2). The antibody to TGF#2 neutralized TGF,2 activity, having no effect on TGF# 1 activity. The preimmune rabbit control antibody (IgG-fraction; Sigma Chemical Co.) had no neutralizing effect on either TGF#31 or TGFfl2.
CCL64 assay. The assay was based on the procedure described by Ikeda et al. and Tucker et al. (14, 15) . CCL64 mink lung epithelial cells 
Results
Low B cell responses to SAC correlate with increased TGFf3 production in HIV+ PBMC. PBMC from a group of 32 HIV+ individuals, whose clinical characteristics are described in Table I, were stimulated with SAC. SAC-induced proliferation in the HIV+ cohort was significantly (P < 0.02) lower than in age-matched healthy heterosexual volunteers (n = 32) (Fig. 1) .
To investigate the role of TGFi3 in this diminished SAC response, patient samples were studied simultaneously for SAC-induced proliferation and TGF,B production. Serum-free supernatants from 24-h cultures of PBMC were tested in the CCL64 assay in which TGF,B inhibits proliferation of lung epithelial cells. The results from these experiments demonstrated that PBMC from HIV+ donors spontaneously released significantly higher amounts (P < 0.0001) ofTGF,3 as compared with the control group (Fig. 1) . Only low amounts of TGF,B (< 60 pg/ml) were detected in nonacidified samples, indicating that most of the TGF,3 activity secreted by HIV-or HIV+ PBMC was in a latent form. Analysis of randomly selected samples in the LAF assay, where TGF,B inhibits IL-1-induced proliferation of thymocytes, showed comparable levels of TGF,B in the culture supernatants (data not shown). Analysis of these data revealed a high degree of correlation between SAC stimulation indices (SI) and TGFf levels (r = -0.7, P = 0.0001) (Fig. 2) TGFf3 inhibition of T cell-independent B cell proliJeration.
To define in more detail the direct effects of TGF, on B cells, purified (monocyte and T cell depleted) B cell populations were stimulated with SAC or EBV and exogenous TGFf (either purified or recombinant) was added. Fig. 3 shows the effect ofTGFf on SAC or EBV-induced B cell proliferation. Proliferation induced by either type of B cell activator was strongly inhibited by TGFf in a dose-dependent manner. In three separate experiments, SAC-induced B cell proliferation was reduced by more than 66% at 1 ng/ml TGFI. The mean values for suppression of the EBV response were 47 and 56% depending on the dilution of the EBV-containing B95-8 supernatants.
Even at 0.1 ng/ml TGF3, a significant B cell suppression could be observed in the SAC-and EBV-stimulated cultures, which was more than 20% from the values obtained omitting this cytokine. Collectively, these data demonstrate that TGFJ is a very potent and direct inhibitor of B cell proliferation. Furthermore, it is operative even in the setting of T cell-independent stimuli. Additional experiments showed that TGF3 effects of similar magnitude, as described above where TGFJ was present during the entire culture period, are seen when B cells were only exposed to TGFf during the first 24 h with the B cell activator (not shown).
Inhibition ofB-cell proliferation by SN from HI V+ PBMC: neutralization by anti-TGFj3. Having defined the conditions under which purified TGF3 can directly inhibit B cell responses, we analyzed whether the activity in the conditioned (Fig. 5 A) . There was no apparent difference in the minimal effective doses of TGFj3 nor in the levels of inhibition at the highest concentrations of TGF3 tested. B cells were then purified and stimulated with EBV to directly test their TGF3 sensitivity. TGFf caused similar inhibition of EBV-induced proliferation in cells from HIV+ and HIV-donors (Fig. 5  B) . The results shown in Fig. 5 [3H]thymidine uptake by only 47±12%. Antibody to TGFf increased the proliferation of HIV-PBMC by 122±43%. In cells from HIV+ patients, anti-TGF,B caused a significant (P < 0.01) increase (183-528%) in proliferation. The antibody effects were more pronounced in PBMC cultures with lower SAC responses (Table I) . These experiments suggest that endogenously produced TGFf inhibits B cell proliferation in HIV+ PBMC. TGFI and B cell differentiation. As the effects of TGFf on B cell function are not restricted to inhibition of antigen or mitogen-induced proliferation, we studied the influence ofpurified TGFf and SN from HIV+ PBMC on B cell differentiation. Low concentrations of purified TGF/3 (100 pg/ml) were able to reduce PWM-induced B cell differentiation (Fig. 6 ), resulting in a significant reduction in the PWM-induced IgG levels (P = 0.01; n = 8). At 1 ng/ml of TGFJ the PWM stimulation was completely inhibited. This culture system was also chosen for experiments with HIV+ culture supernatants because of its high sensitivity to TGF,B. When 24-h SN from HIV+ PBMC were tested at a 1:5 dilution in this assay, the PWM-induced production of IgG was completely inhibited. At a 1:20 dilution, IgG levels were still inhibited by more than 60%. This inhibitory effect was completely neutralized by antiserum to TGFf 1 + 2. The TGF32-specific antiserum and control rabbit IgG had no significant effects (Fig. 7 A) . Furthermore, 24-h SN from HIV-PBMC had no detectable inhibitory effect on IgG production. The same set of conditioned media from HIV+ PBMC also inhibited IgM and IgA production (Fig. 7, B and C) . These results indicate that the levels of TGF1 activity in HIV+ PBMC SN are sufficient to inhibit B cell differentiation.
Discussion
HIV infection is often associated with hypergammaglobulinemia, the presence ofautoantibodies with diverse specificities and deficient production of antibodies to new antigens. In addition, EBV-associated B-lymphoproliferations occur at increased frequency in these patients (17, 18 tive when the factor is added early and that it has only minor effects on already activated cells (23 (31) and IgA secretion (32) . Other cytokines, such as IL-6 are likely to also be involved in the subclass imbalance, since in transgenic mice that overexpress IL-6 in B cells, IgG I is the major contributor to the hypergammaglobulinemia (33) . Furthermore, in murine B cells from Peyer's patches, IL-6 is the most potent stimulus of IgA secretion (34) . These studies suggest that IL-6 and TGFJ. have at least the potential to contribute to the imbalance of the subclass distribution of the immunoglobulins that are produced in HIV infection.
A paradox also exists with respect to B cell growth regulation in HIV infection (5, 6) . In contrast to the reduced B cell proliferation in vitro reported here and in other studies, a very high frequency of B cell lymphomas is seen in HIV+ patients (17, 18) . Two aspects of TGF# action are significant in this context. A critical determinant in the initial phase of the development of these tumors is a lack of adequate T cell control of reactivated EBV infection. As a potent inhibitor of both T helper cell, and cytotoxic T cell function (35) , TGFf likely contributes to the deficit in T cell surveillance. The role of T cell defects in the development of B cell lymphomas is also supported by the emergence of similar tumors in immunosuppressed transplant recipients (36) . Furthermore, recent observations in SCID mice, show that in the absence of normal immune function, injection of blood cells from EBV+ humans leads to the development of EBV-positive B cell proliferation (37 
